PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijcepLink to Publisher's site
 
Int J Clin Exp Pathol. 2010; 3(8): 755–762.
Published online 2010 October 1.
PMCID: PMC2993225

Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma

Abstract

Anaplastic thyroid carcinoma (ATC) is a highly aggressive neoplasm resistant to radiation and chemotherapy. Epithelial-mesenchymal transition (EMT) generating cells with stem cell characteristics have been reported to be associated with chemoradioresistance in cultured cells. However, EMT and stem cell properties in ATC have not been fully investigated. In this study, we retrieved 2 thyroidectomy specimens of ATC with coexisting well differentiated thyroid carcinomas (DTCs) including one papillary carcinoma (PTC) and one follicular carcinoma (FTC). We used im-munohistochemistry to examine the expression of stem cell markers (nestin, CD133 and CD44) and a marker for EMT (E-cadherin). Intense expressions of nestin, CD133 and CD44, and no expression of E-cadherin were observed in both ATCs. In contrast, the PTC and FTC, and non-neoplastic thyroid tissue in both cases were negative for nestin and positive for E-cadherin. The expressions of CD133 and CD44 were variable in the PTC, FTC, and non-neoplastic thyroid tissue and were at a lower level of expression of these markers in the overall pattern. The results confirmed EMT, demonstrated the stem cell phenotype in ATC, and revealed the difference in expression of these markers between ATC and DTCs/non-neoplastic thyroid tissue. Nestin may be the most specific marker for stemness in ATC by immuno-histochemial staining. The results warrant future studies on a large series of cases in order to gain the understanding of the tumor biology and to provide molecular basis for restoring the sensitivities to clinical therapies.

Keywords: Anaplastic thyroid carcinoma, cancer stem cell, epithelial-mesenchymal transition, follicular thyroid carcinoma, immunohistochemistry, papillary thyroid carcinoma

Introduction

Anaplastic thyroid carcinoma (ATC) is a rapidly fatal malignant neoplasm. The overall median survival is 2.5-6 months [1]. Despite advances in the understanding and treatment of other malignancies during the past decades, little improvement has occurred in ATC. Surgery, radiotherapy, and standard chemotherapy do not meaningfully improve survival [2].

It has been observed that differentiated thyroid carcinoma (DTC) affects the risk of developing ATC. Many cases of ATC (from 23% to 78%) have preexisting or coexisting DTCs of follicular cell origin [3-5]. Therefore, it is thought that most ATCs result from dedifferentiation or anaplastic transformation - an intratumoral evolution [6, 7].

Epithelial-mesenchymal transition (EMT) is a dedifferentiation program that converts epithelial cells into a mesenchymal phenotype and is involved in embryogenesis and used pathologically during cancer progression [8]. E-cadherin is a central component of cell junctions and is required for the cell to cell adherens of epithelia [9, 10]. Loss of functional expression of E-cadherin protein and/or transcriptional repression of its mRNA is presently considered as the hall mark of EMT [11]. The consistent absence of E-cadherin expression in ATCs has been reported in the literature [12-14]. Thus, the anaplastic transformation of DTCs is an example of EMT. However, the biologic characteristics of the transformed tumor cells (ATC cells) have not been fully investigated.

Cancer stem cells (CSCs) have been increasingly evaluated in various tissues and tumors and are thought to be responsible for tumor genesis, recurrence and chemoradioresistance [15-17]. The existence of stem cell-like properties in cancer cells has been demonstrated in hematological cancers and various solid malignant neoplasms [18-20]. However, to our knowledge, there are very few studies of stemness in ATC reported in the literature [21-24]. Among them, only two studies are on the stemness phenotype in ATC. Both studies were cultured cell line-based and the evaluations were based on only one stem cell marker - CD133. Therefore, expressions of stem cell antigens in ATC have not been fully studied.

Identification of specific molecular alterations and mechanisms that underlie this anaplastic transformation is a powerful tool for gaining insight into tumor biology and the discovery of therapeutic targets. In this study, we used im-munohistochemistry to examine the expression of multiple markers for stem cell properties and EMT in ATC with comparison with coexisting DTCs (PTC and FTC) and adjacent non-neoplastic thyroid tissue to evaluate the change in the expression profile that occurs during the transformation of DTC into ATC, to find stem cell marker(s) specific for ATC, and to gain understanding of thyroid tumor progression.

Materials and methods

Archival thyroidectomy specimens were obtained from 2 patients with ATC and contiguous DTCs (1 PTC and 1 FTC, respectively) and adjacent non-neoplastic thyroid tissue. Neither of these patients had preoperative treatment for the thyroid tumors. This study protocol was approved by the Institutional Review Board of the University of Texas Health Science Center at Houston.

Immunohistochemical Staining

Immunohistochemial stains were performed on formalin-fixed and paraffin-embedded unstained sections of 4 μm thickness. Four primary antibodies were employed to detect the following antigens: EMT-associated marker: E-Cadherin (ZYMED Laboratories Inc., San Francisco, USA); and stem cell-associated markers: Nestin (Abcam, Cambridge, MA) and CD133 (Abcam) and CD44 (Novocastra, Newcastle upon Tyne, UK).

The slides were stained in an automatic immu-nostainer using a standard avidin-biotin complex staining procedure. Immunohistochemical reactions were developed with diaminoben-zidine as the chromogenic peroxidase substrate, and the slides were counterstained with hematoxylin.

Assessment of Immunohistochemical Staining

Chromogenic signal and subcellular expression pattern were assessed by bright-field microscopy. Both staining intensity and extensiveness were evaluated for each marker. Staining intensity was graded as negative (0), weak (1+), moderate (2+), and strong (3+). Staining extensiveness was the percentage of tumor cells positively stained with a range from 0% to 100%. The subcellular expression pattern was evaluated and characterized as: nuclear, cyto-plasmic, or plasmalemmal locations.

Results

Microscopic examination showed 2 ATC cases, one with PTC component and the other with FTC transitioning to the ATCs.

Extensive and moderate or strong expressions of cytoplasmic nestin, cytoplasmic CD133, and plasmalemmal CD44, and no expression for E-cadherin were observed in both ATCs. In contrast, the PTC and FTC, and non-neoplastic thyroid tissue in both cases were negative for nestin and positive for E-cadherin (plasmalemmal staining). The expressions of CD133 and CD44 were variable in the PTC, FTC, and non-neoplastic thyroid tissue and were at a lower level of expression of these markers in the overall pattern (intensity and extensiveness) in both cases.

The details of immunostaining results are summarized in Table 1. The expressions of these markers are demonstrated in Figure 1 and Figure 2.

Figure 1
Immunohistochemical staining of nestin in : A. anaplastic thyroid carcinoma (Original magnification × 400); B. adjacent non-neoplastic thyroid tissue (Original magnification × 400); C. papillary thyroid carcinoma component (lower portion)contiguous ...
Figure 2
Immunohistochemical staining ofE-cadherin in: A. anaplastic thyroid carcinoma (original magnification × 400); B. adjacent non-neoplastic thyroid tissue (original magnification × 400); C. papillary thyroid carcinoma component (original ...
Table 1
Immunoreactivities for nestin, CD133, CD44, and E-cadherin in ATC, PTC, FTC, and nonneoplastic thyroid tissue

Discussion

This study using immunohistochemical staining demonstrates the stemness phenotype in ATC with nestin as the most specific marker and accords with EMT in ATC.

The absence of E-cadherin in ATCs in contrast to the expression of E-cadherin in DTCs and non-neoplastic thyroid tissue in this study is consistent with previous reports in the literature [12-14] and supports the EMT process from DTC to ATC [25]. The aggressive behavior of ATC accords with the concept that the EMT promotes the invasiveness of the malignant neoplasms [26].

Expressions of several stem cell markers have been identified in various tissues/tumors. However, it is highly debated whether or not these CSCs originate from resident stem cells which progressively acquire a malignant phenotype or from dedifferentiation of mature cells within the organs.

Recent studies have shown evidence suggesting that the two novel concepts, EMT and CSCs, have merged in cancer biology. The studies have consistently demonstrated that EMT cells acquire stem cell characteristics in breast, ovary, pancreas and prostate cancers [27-32]. Mani and co-workers also noted that the maintenance of the stem cell state depends on continuous EMT-inducing signals in cultured cells with EMT [27]. Moreover, it has been shown that EMT and cancer stem cell-like phenotypes facilitate chemoresistence in recurrent ovarian cancer and pancreatic cancer cells [30, 31]. Additionaly recent studies suggest that some important signaling pathways involved in stemness also act as potent EMT inducers in different cellular or biological contexts, e.g., EMT promoting Smad complexes, snail family, Wnt/β-catenin and Notch pathways [33, 34]. Wellner et al also proposed that ZEB1 linked EMT-activation and stemness-maintenance by suppressing stemness-inhibiting microRNAs [35]. Therefore, CSCs may be generated by EMT of differentiated cells by acquiring specific mutations that endow them with stem cell-like properties [36].

Some of stem cell markers are commonly expressed in multiple organs/tissues/tumors while the others are more organ/tissue/tumor specific.

Nestin is an intermediate filament protein. It was initially found as a stem cell marker in the brain and brain tumors [37]. Lately, nestin expression has been observed in various tissues and tumors and in proliferating vascular endo-thelial cells. Therefore, nestin is now known as a stem cell marker as well as a novel angio-genesis marker of neovascularization [38]. Nestin expression in tumor cells and vascular endothelial cells has been detected in many types of neurogenic tumors and in various types of epithelial and mesenchymal tumors, e.g., in cultured pancreatic mesenchymal stem/ precursor cells [39], triple negative breast carcinoma tissue [40], dermatofibrosarcoma protu-berans [41], rhabdomyosarcomas [42], several pediatric tumors in the region of the kidney (Wilms tumor,, mesoblastic nephroma, malignant rhabdoid tumor and desmoplastic small round cell tumor) [43] and in proliferating endothelial cells in colorectal cancer tissue [44]. Moreover, it is reported that nestin expression correlates with tumor malignancy and invasive-ness in neurogenic tumors [45] and the nestin-positive populations of tumor cells have a primitive phenotype, which supports the cancer stem cell hypothesis [46].

In our study, only ATC cells express nestin while losing E-cadherin, in contrast to DTCs and non-neoplastic thyroid tissue. This suggests that the anaplastic thyroid carcinoma cells arise via epithelial-mesenchymal transition from differentiated thyroid carcinoma and in the process, gain the phenotype of stemness. There is only one study evaluating nestin in ATC found in the literature [24]. In that study Yamada et al “unexpectedly” found that nestin mRNA was decreased in ATC and increased in differentiated thyroid tumors and normal thyroid cells. One possibility is that the increased nestin protein expression that we observed might not be transcriptional but could be post-transcriptional or post-translational. Further studies are required to elucidate the mechanisms behind these seemingly discordant findings.

Our current study is the first observation that demonstrates nestin antigen expression in ATC by immunohistochemical staining in contrast to its absence in DTCs and adjacent non-neoplastic thyroid tissue. Furthermore, because nestin is also a marker of mesenchymal stem cells [41], its detection in ATC may reflect the acquisition of mesenchymal stemness. Therefore, nestin may serve as a specific stem cell marker for ATC.

CD133 is identified as a stem cell marker in a variety of normal and cancerous tissues. Studies have shown that the expression of CD133 predicted for non-response to chemotherapy in colorectal cancer [47], the survival time of patients with CD133 positive neuroblastoma cells was shorter than that of CD133 negative patients [48] and that CD133 could be a therapeutic target in hepatocellular and gastric cancers [49]. In spite of CD133 as a well known stem cell marker in many other tumors/tissues, there are only two studies of CD133 antigens in ATC has been reported [22,23]. The first study of in vitro identification and characterization of CD133+ cancer stem-like cells in ATC cell lines was reported by Zito et al in 2009 [22]. They detected CD133 antigen in cultured ATC cells by flow cytometry and found that the CD133+ cells were more chemoresistant than CD133- ATC cells. Lately, Friedman and co-workers again observed CD133 expression in ATC cell lines and other stem cell properties [23]. The expression of CD133 in patient ATC tissue demonstrated in our current study is consistent with the aforementioned two previous reports in the literature.

In regard to subcellular compartmentalization, the CD133 expression in our current study is predominantly cytoplasmic. The cytoplasmic expression of CD133 has been observed in other types of tumors such as hepatocellular carcinoma and ovarian carcinoma [50, 51]. Moreover, the ovarian cancer patients have poor prognosis if there is diffuse cytoplasmic expression of CD133 [51]. In regard to intensity and extensiveness of CD133 expression, Song et al showed that hepatocellular carcinoma patients with high CD133 expression had shorter overall survival and higher recurrence rates compared to patients with low CD133 expression [52]. Accordingly, in the current study, the ATCs demonstrate more overall expression of CD133 than DTCs, consistent with a poorer prognosis of ATCthan DTCs.

The expression of CD133 in DTCs (PTC and FTC) and at a lower level than that in ATC observed in the current study accords with the study by Mitsutake et al in that a side population with several up-regulated genes related to stemness was identified in PTC (NPA cell line) and FTC (WRO cell line) at a lower level than that in ATC cell lines [21]. However, Friedman and colleagues in their study could not detect CD133 expression in PTC cell lines (both NPA and TPC cell lines) and human normal thyroid cells neighbored to ATCs by immunohistochemistry [23]. Therefore, more future studies are needed to define the specificity of CD133 as a thyroid stem cell marker although the expression of CD133 in ATC likely reflects stemness.

CD44 is identified to be another stem cell marker and its expression was observed in colon, liver, breast, and head and neck cancers [50, 53-55]. CD 44 antigen expression as a stem cell marker in thyroid tissue/tumors has not been reported. This current study identified CD44 expression in thyroid neoplastic and non-neoplastic tissue. The expression in the ATCs is at a higher level than that in the DTCs and non-neoplastic thyroid tissue adjacent to the ATCs. Thus, CD44 may also be one of the stem cell markers in ATC.

The stemness in ATC demonstrated by this study is further supported by the finding of down regulation of stemness-inhibiting microR-NAs in ATC cells by Braun J et al [56]. The DTCs (PTC and FTC) and adjacent non-neoplastic thyroid tissue in our study have a certain degree of expression of CD133 and CD44, which suggests that these two markers are not specific for stemness expression in ATC. This is agreed by the observation of Zito et al [22]. They found that two of four ATC cell lines did not express CD133, implicating that the mere presence of CD133 was not sufficient for characterizing the stemness and there must be some other unidentified markers. The current study demonstrates that nestin may be a key marker to indicate the stemness in ATC.

In summary, this is the first study using immu-nostaining that demonstrates expressions of multiple stem cell markers (nestin, CD133, and CD44) in ATC tissue with comparison to coexisting well differentiated thyroid carcinomas (PTC and FTC) and adjacent non-neoplastic thyroid tissue. Among these three markers, nestin is the most specific one characterizing the stemness of ATC. The expression of stem cell markers with the concomitant loss of E-cadherin is consistent with epithelial mesenchymal transition associated with the stem cell phenotype in ATC. The identification of the properties of cancer stem cells in ATC may be served as a molecular basis for developing targeted therapy for this tumor. The results of our study warrant future studies on a large series of cases.

Acknowledgments

The authors would like to thank Ms. Pamela K. Johnston, HT (ASCP), and Mr. Richard A. Breckenridge, HT (ASCP) for their technical assistance, Ms. Bheravi Patel for secretarial and graphic design expertise.

References

1. Ordonez N, Baloch Z, Matias-Guiu X, Evans H, Farid NR, Fagin JA, Kitamura Y, Tallini G, Eng C, Haigh PI, Faquin WC, Sugitani I, Giuffrida D, Boerner S. Undifferentiated (anaplastic) carcinoma. WHO classification of tumors - pathology and genetics of tumours of endocrine organs. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Lyon, France: IARC press; 2004. p. 77.
2. Tennvall J, Lundell G, Wahlberg P, Bergenfelz, Brimelius L, Akerman M, Skog A-LH, Wallin G. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86:1848–1853. [PMC free article] [PubMed]
3. McIver B, hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR. Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery. 2001;130:1028–34. [PubMed]
4. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990;66:321–330. [PubMed]
5. Nishiyama RH, Dunn EL, Thompson NW. Anaplastic spindle-cell and giant-cell tumors of the thyroid gland. Cancer. 1972;30:113–127. [PubMed]
6. Albores-Saavedra J, Hernandez M, Sanchez-Sosa S, Simpson K, Angeles A, Henson DE. Histologic variant of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroidglobulin inclusions. Am J Surg Pathol. 2007;31:729–736. [PubMed]
7. Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol. 1985;83:135–158. [PubMed]
8. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–142. [PubMed]
9. Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem. 1990;59:237–252. [PubMed]
10. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996;84:345–357. [PubMed]
11. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118:277–279. [PubMed]
12. Aratake Y, Nomura H, Kotani T, Marutsuka K, Kobayashi K, Kuma K, Miyauchi A, Okayama A, Tamura K. Coexistent anaplastic and differentiated thyroid carcinoma. Am J Clin Pathol. 2006;125:399–406. [PubMed]
13. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg. 2006;191:581–587. [PubMed]
14. Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg. 2007;142:717–729. [PubMed]
15. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542–2556. [PubMed]
16. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–284. [PubMed]
17. Brown RE. Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. Arch Pathol Lab Med. 2009;133:568–579. [PubMed]
18. Huntly BJ, Gilliland DG. Leukemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005;5:311–321. [PubMed]
19. Vescovi AL, Galli R, Reynolds BA. Brain tumor stem cells. Nat Rev Cancer. 2006;6:425–436. [PubMed]
20. McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol. 2010 Jun 17. [Epub ahead of print] [PMC free article] [PubMed]
21. Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V, Yamashita S. Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology. 2007;148:1797–1803. [PubMed]
22. Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, Pizzolanti G, Galluzzo A, Giordano C. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One. 2008;3:e3544. Epub 2008 Oct 28. [PMC free article] [PubMed]
23. Friedman S, Lu M, Schultz A, Thomas D, Lin RY. CD133+ anaplastic thyroid cancer cells initiated tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One. 2009;4(4):e5395. Epub 2009 Apr 30. [PMC free article] [PubMed]
24. Yamada H, Takano T, Ito Y. Expression of nestin mRNA in a differentiation marker in thyroid tumors. Cancer Lett. 2009;280:61–64. [PubMed]
25. Caillou B, Malouf G. Anaplastic cancer of the thyroid: an example of epithelial-mesenchymal transition. Ann Pathol. 2009;29:S67–S68. [PubMed]
26. Guarino M. Eithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol. 2007;39:2153–2160. [PubMed]
27. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715. [PMC free article] [PubMed]
28. Morel A-P, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008;3:1–7. [PMC free article] [PubMed]
29. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009;69:2887–2895. [PMC free article] [PubMed]
30. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets. 2010;10:268–278. [PubMed]
31. Du Z, Qin R, Wei C, Wang M, Shi C, Tian R, Peng C. Pancreatic cancer cells resistant to chemoradiotherapy rich in “stem-cell-like” tumor cells. Dig Dis Sci. 2010 Aug 4. [Epub ahead of print] [PubMed]
32. Giannoni E, Bianchini F, Masieri L, Semi S, Torre E, Calorini L, Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010 Aug 10. [Epub ahead of print] [PubMed]
33. Fuxe J, Vincent, de Herreros AG. Transcriptional crosstalk between TGFbeta and stem cell pathways in tumor cell invasion: Role of EMT promoting Smad complexes. Cell Cycle. 2010;9:2363–2374. [PubMed]
34. Olmeda D, Moreno-Bueno G, Sarrio D, Palacios J, Cano A. Invasion program of normal and cancer stem cells. In: Bapat S, editor. Cancer stem cells, identification and targets. New Jersey: John Wiley & Sons, Inc; 2009. pp. 177–178.
35. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schuler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRMAs. Nat Cell Biol. 2009;11:1487–1495. [PubMed]
36. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion: The origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer. 2005;5:899–904. [PubMed]
37. Tohyama T, Lee VM, Rorke LB, Marvin M, Mckay RD, Trojanowski JQ. Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest. 1992;66:303–313. [PubMed]
38. Mokry J, Cizkova D, Filip S, Ehrmann J, Osterreicher J, Kolar Z, English D. Nestin expression by newly formed human blood vessels. Stem Cells Dev. 2004;13:658–664. [PubMed]
39. Gallo R, Gambelli F, Gava B, Sasdelli F, Tellone V, Masini M, Marchetti P, Dotta F, Sorrentino V. Generation and expansion of multipotent mesenchymal progenitor cells from cultured human pancreatic islets. Cell Death Differ. 2007;14:1860–1871. [PubMed]
40. Liu C, Chen B, Zhu J, Zhang R, Yao F, Jin F, Xu H, Lu P. Clinical implications for nestin protein expression in breast cancer. Cancer Sci. 2010;101:815–819. [PubMed]
41. Sellheyer K, Nelson P, Krahl D. Dermatofibrosarcoma protuberans: a tumour of nestin-positive cutaneous mesenchymal stem cells? Br. J. Dematol. 2009;16:1317–1322. [PubMed]
42. Kobayashi M, Sjoberg G, Soderhall S, Lendahl U, Sandstedt B, Sejersen T. Pediatric rhabdomyosarcomas express the intermediate filament nestin. Pediatr Res. 1998;43:386–392. [PubMed]
43. Murphy AJ, Viero S, Ho M, Thomer PS. Diagnostic utility of nestin expression in pediatric tumors in the region of the kidney. Appl Immunohistochem Mol Morphol. 2009;17:517–523. [PubMed]
44. Teranishi N, Naito Z, Ishiwata T, Tanaka N, Furukawa K, Seya T, Shinji S, Tajiri T. Identification of neovasculature using nestin in colorectal cancer. Int J Oncol. 2007;30:593–603. [PubMed]
45. Ehrmann J, Kolar Z, Mokry J. Nestin as a diagnostic and prognostic marker: Immunohistochemical analysis of its expression in different tumour. J Clin Pathol. 2005;58:222–223. [PMC free article] [PubMed]
46. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells – perspectives in current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006;66:9339–9344. [PubMed]
47. Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, Salto-Tellez M. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 2010;23:450–457. [PubMed]
48. Tong Q-S, Zheng L-D, Tang S-T, Ruan Q-L, Liu Y, Li S-W, Jiang G-S, Cai J-B. Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr. 2008;4:58–62. [PubMed]
49. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber H-P, Van Orden KL, Moore PA, Ruben SM, Carter PJ. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008;99:100–109. [PMC free article] [PubMed]
50. Zenali MJ, Tan D, Li W, Dhingra S, Brown RE. Stemness characteristics of fibrolamellar hepatocelular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma. Ann Clin Lab Sci. 2010;40:126–134. [PubMed]
51. Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G. CD133 antigen expression in ovarian cancer. BMC Cancer. 2009;9:221. [PMC free article] [PubMed]
52. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008;62:1212–1218. [PubMed]
53. Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14:6751–6760. [PubMed]
54. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:10153–10163.
55. Pries R, Witrkopf N, Trenkle T, Nitsch SM, Wollenberg B. Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer. In Vivo. 2008;22:89–92. [PubMed]
56. Braun J, Hoang-Vu C, Dralle H, Huttelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinoma. Oncogene. 2010;29:4237–4244. [PubMed]

Articles from International Journal of Clinical and Experimental Pathology are provided here courtesy of e-Century Publishing Corporation